Item type: | Article | ||||
---|---|---|---|---|---|
Journal or Publication Title: | Biology of Blood and Marrow Transplantation | ||||
Publisher: | Elsevier | ||||
Place of Publication: | NEW YORK | ||||
Volume: | 22 | ||||
Number of Issue or Book Chapter: | 10 | ||||
Page Range: | pp. 1781-1791 | ||||
Date: | 2016 | ||||
Institutions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) | ||||
Identification Number: |
| ||||
Keywords: | BONE-MARROW-TRANSPLANTATION; CHRONIC MYELOGENOUS LEUKEMIA; CONSENSUS DEVELOPMENT PROJECT; WORKING GROUP-REPORT; LONG-TERM SURVIVAL; UNRELATED DONORS; CHRONIC GVHD; PROGNOSTIC-FACTORS; RANDOMIZED-TRIAL; PREDICTIVE FACTORS; Risk factor; Outcome; Chronic graft-versus-host disease; Allogeneic stem cell transplantation | ||||
Dewey Decimal Classification: | 600 Technology > 610 Medical sciences Medicine | ||||
Status: | Published | ||||
Refereed: | Yes, this version has been refereed | ||||
Created at the University of Regensburg: | Yes | ||||
Item ID: | 42972 |
Abstract
Chronic graft versus host disease (cGVHD) is the most frequent long-term complication after allogeneic stem cell transplantation (allo-SCT) and results in impaired quality of life and increased long-term morbidity and mortality. We analyzed 243 patients with cGVHD, documented according to the 2005 revised National Institutes of Health consensus criteria, to identify risk factors for the ...

Abstract
Chronic graft versus host disease (cGVHD) is the most frequent long-term complication after allogeneic stem cell transplantation (allo-SCT) and results in impaired quality of life and increased long-term morbidity and mortality. We analyzed 243 patients with cGVHD, documented according to the 2005 revised National Institutes of Health consensus criteria, to identify risk factors for the occurrence of cGVHD and outcomes for the patients with cGVHD. Patients without evidence of cGVHD (n = 147) were used as controls. Performing univariate and multivariate Cox regression analyses, we identified prior acute GVHD grades III or IV (hazard ratio [HR], 2.01; P =.005), use of peripheral blood stem cell graft (HR, 2.10; P =.03), and HLA-mismatched allo-SCT from unrelated donor (HR, 1.57; P =.02) as independent risk factors for cGVHD. Performing Kaplan-Meier analyses, progressive compared with de novo and quiescent onset of cGVHD and a platelet count of less than 100/nL compared with more than 100/nL at the time of cGVHD onset were associated with a significantly increased cumulative incidence of transplantation-related mortality (TRM) and significantly decreased overall survival. Furthermore, we found a significantly higher incidence of TRM in patients with severe cGVHD compared with patients without cGVHD (58% versus 11%, P <.0001). However, in subgroup analysis, patients with severe cGVHD and involvement of the lung, liver, or gastrointestinal (GI) tract had a 6.5-fold significantly higher incidence of TRM (72%), whereas patients with severe cGVHD lacking lung, liver, or GI involvement had only a 2.8-fold significantly higher incidence of TRM (31%) compared with patients without cGVHD (11%; P <.0001 and P =.03). Patients without lung, liver, or GI involvement did not have a significantly different TRM compared with patients with moderate cGVHD (31% versus 25%, P =.52). In conclusion, we confirm prior known risk factors for the occurrence of cGVHD and subsequent mortality and we provide evidence that the presence of lung, liver, or GI involvement in patients with severe cGVHD defines a subgroup with high mortality after allo-SCT; however, in the absence of these risk factors, the outcome appears not to be impaired compared with moderate cGVHD. (C) 2016 American Society for Blood and Marrow Transplantation.
Metadata last modified: 17 Mar 2020 12:08